Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 11/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214062 | 0.91 | POLB (0.42) | IL2LMNACREBBPPOLBUSP2 | |
| SCHEMBL8259711 | 0.87 | IL2 (0.46) | IL2LMNAPOLBUSP2KDM4E | |
| SCHEMBL15214063 | 0.85 | IL2 (0.44) | IL2LMNAPOLB | |
| SCHEMBL17435148 | 0.85 | IL2 (0.40) | IL2LMNACREBBPPOLBUSP2 | |
| SCHEMBL15214060 | 0.83 | IL2 (0.43) | IL2LMNAPOLB | |
| SCHEMBL15214066 | 0.82 | IL2 (0.46) | IL2LMNAPOLBUSP2KDM4E | |
| SCHEMBL15214067 | 0.81 | IL2 (0.45) | IL2LMNAPOLBUSP2KDM4E | |
| SCHEMBL15942556 | 0.81 | IL2 (0.49) | IL2LMNACREBBPPOLBUSP2 | |
| SCHEMBL15214064 | 0.81 | IL2 (0.43) | IL2LMNAPOLBUSP2KDM4E | |
| SCHEMBL5550955 | 0.81 | IL2 (0.64) | IL2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493427-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-1848435-B1 | COMPOUNDS AGAINST INFLAMMATIONS AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-9090570-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 21/4885LMNA 3271/4885CREBBP 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.